Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where do you see that?
Someone shorted 5.67% of the float that’s why we tumbled -1.7 million shares last week …… why , what do they know we don’t
They had a PES conference to discuss the phase-2 resulted may 2-5 where they may have released the info but I can’t find it anywhere . But may 7th was a high volume day so someone bought a lot of shares between 3-3.40$
First they were saying the 9th, then they said the 16th - now it’s the 13th after close . Then there’s a JPM securities life science conference on the 14th and annual stock holders meeting on the 16th . As far as I know - I do a lot of research and call the company occasionally
I thought phase II results were coming out mid May?
Low volume , grab some cheap ones - gotta wait til it plummets -2.50-2.60 maybe good luck . Quarterly report is now may 13 3:00 - hoping it’s great , should at least be good beat by .03
Wow , got some cheap 2.88 today got some 3’s yesterday . Guess we gotta wait and see . No news til may 14th ,quarterly
Gonna run today IMO , strong day yesterday - nice dip , got some cheap one for flipping . Let the games begin
I posted this on biotech values board last week
RZLT dippers. Strong stock on the rise.
Oh I’m not selling! I look at this drop as an opportunity to buy more.
We are up 189% over the last 3 mths . To reduce exposure after this run is simply good risk management .
A large enough sell order to reduce exposure ,can trigger a cascade of stop loss orders .
Market will be looking at near term P2 DME data as next major catalyst .
JMO
Kiwi
RZLT...........................................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
Can’t seem to buy any shares under 3.25 , looks Like its trading between 3.30-3.50 . No big pull back but lower volume ?? Get what you can I guess
Sorry earning are farther out not 5/9/24
With this decent volume pull back , price should drop below 3 tomorrow or the next couple days . Time to reload 2.70-2.80 gap . If your playing it
- if your holding it wait for 8-10$ imo
Earnings 5/9/24
Another huge vol day to the upside ( at least so far today ) , so congrats on accumulating .
The p2 DME trial has ended about now ...so its now down to data checking and publishing the data .
I have no idea if the recent increase in PPS is a data leak , accumulation for a buy out or simply due to speculative positioning .
Guess we will know in " the fullness of time "
Kiwi
I’m following and accumulating!
RMB. P2 DME . data due late next month ( my guess )
https://www.rezolutebio.com/for-patients/living-with-dme/
P1b results of same drug
https://ir.rezolutebio.com/news-events/press-releases/detail/295/rezolute-announces-positive-study-results-for-rz402-an
Kiwi
RZLT. P2 DME trial ending approximately next week ...now data chk / cleaning etc ...results probably late next month .
Anyone else following this ?
https://ir.rezolutebio.com/news-events/press-releases/detail/322/rezolute-completes-enrollment-of-its-phase-2-study-in
Kiwi
RSI 74 , Williams % -8 , looks ready to blow 3.75+ IMO price 2.60
Up close to 80% since my initial purchase. Reduced my position somewhat going into the CPI report tomorrow as a bad report will mean a sell off in spec biotechs as well as small caps .
Simple risk mgt.
Kiwi
RZLT...........................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
DME P2 results due Q2
https://www.rezolutebio.com/for-patients/living-with-dme/
Kiwi
RZLT..................................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
CFO was granted 275,000 options a $0 on 1/23/24 that start vesting in Jan 25
That wasnt enough for him
So far he has bt on the open market ....another 159,000 shares for himself and his kids.
139,000 of those since 2/16
Kiwi
3/19. CFO open mkt purchase of 20,000 shares
3/19 CMO open mkt purchase of 10,000 shares
Kiwi
This is a new position for Nantahala Capital ....4,118,164 shares
Kiwi
March 11 (Reuters) - Rezolute Inc ( RZLT ):
* NANTAHALA CAPITAL MANAGEMENT LLC REPORTS 9.9% PASSIVE STAKE IN REZOLUTE INC AS OF AS OF FEB 29 - SEC FILING Source text for Eikon: Further company coverage:
Kiwi
RZLT................................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
RMB ...comparing RZLT and EYEN ...a quick Look.
Last earnings report EYEN had $21m cash and were losing $7.3 m a qt ....so you know a huge capital raise is coming if they hope to manufacture and sell their device
RZLT has $96m in cash and are losing $14m a qt ...so their cash on hand will last them well into 2025 ...altho they will probably raise $ on a good DME trial read out ...late May I think .
I'm biased to Bay Area biotechs as I've met people working at some of them and hedge fund managers that invest in them .
They are usually connected to leading edge KOL's at places like Stanford and UCSF and often have them on their advisory boards , even BOD's.
Chk TNYA for instance ( which I also own ...early days )
Good luck
Kiwi
Kiwi, RZLT not giving me a break to buy in as it keeps marching north. I do have to tell you about a drug approval that I did handle correctly (of course you remember Amarin's label expansion). I was in EYEN and they received approval of their drug candidate Monday night. The stock was not behaving as it should have that day and when the approval came in the after market, it did not move at all. I dumped in the after hours market immediately when I saw that. I had intentions of selling on the pop, but there was no pop and the following days it has dropped. Of course it did have a rise during the month prior. Glad to get out.
GD. Well it will be a big deal if they see clinical benefit in DME . I'm also in OCUL ..drug eluting inserts , and you're in EYPT ...injections ( but longer duration between shots ? )
If U have time take a look at UNCY. My wife rounds dialysis clinics ( also did CKD research at Yale ). None of her patients are at goal for serum phosphorous.....and none can afford the copay for the new serum phosphorous lower drug ...Xphanozh ? ...unless co ( ARDX ) pays down their copay ( currently $1,000 a mth ) .
The clinical data for OLC ( UNCY ) looks impressive . Co has also just been granted Orphan Drug designation .
However Co has limited cash and looks to need a capital raise to complete their current pivotal trial .
So if you have time , take a look ...let me know if you see any red flags I'm blind to .
Kiwi
Thanks, Kiwi
Now I am much more conservative in terms of expecting efficacy from
this P2 DME data.
RMB. The P2 DME trial is probably a long shot to show clinically relevant improvement . Dew ( biotech values ) was of the opinion that there was a narrow therapeutic window ( which means I think that at high enough dose to see clinically relevant benefit , you'll probably see a lot more side effects .)
I'm hopefully tho because of the involvement of this KOL ...Robert B Bhisikul MD ..UCSF Prof of Ophthalmology and Retinal Specialist .
UCSF are cutting edge ...I was in a Cardiovascular trial their years ago
Saw your post about this on another board. I am pi$$ed a bit because I had been trying to buy this from about a couple of weeks ago, but it kept running away from me. I was attempting to liquidate something and pick this up and it became a frustrating experience. Maybe I may have a chance if it retraces a bit?
P2 DME trial is fully enrolled with primary completion in April ..results probably in late May
https://www.clinicaltrials.gov/study/NCT05712720?tab=history&a=7
About RZ402
RZ402 is a selective and potent PKI being developed as a potential once-daily oral therapy for the chronic treatment of DME. By inhibiting the activation of kallikrein, RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
RZ402 has been shown to reduce and prevent retinal vascular leakage in animal models by up to 90%. Results from a Phase 1b multiple ascending dose (MAD) study showed that RZ402 was readily bioavailable with dose-dependent increases in systemic exposures.
RZ402 concentrations substantially exceeded target efficacious concentrations based on a combination of in-vitro and in-vivo pharmacology studies in animals, supporting the potential as a once daily therapy for DME.
RZ402 was generally safe and well-tolerated, including at higher doses than previously tested in the single ascending dose (SAD) study.
There were no serious adverse events, adverse drug reactions, or identified risks.
Kiwi
RZLT..................................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
RZLT.......................................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
Mid of May, if RZLT follows EYPT steps, very likely, very strong interests in PII
with fast and over enrollments which foretells strong proof of concept data,
we may see $500-600M MC, $13-15 stock, IMO.
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
385
|
Created
|
01/20/13
|
Type
|
Free
|
Moderators |
"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |